Who are Acetaminophen/Ibuprofen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Acetaminophen and Ibuprofen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acetaminophen-ibuprofen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Acetaminophen/Ibuprofen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acetaminophen/Ibuprofen (Acetaminophen/Ibuprofen) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Analgesic/Antipyretic combination (NSAID + non-NSAID). Area: Pain Management.

marketed Analgesic/Antipyretic combination (NSAID + non-NSAID) Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2), prostaglandin synthesis pathways Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Acetaminophen/Ibuprofen (Acetaminophen/Ibuprofen) — Seoul National University Hospital. This is a fixed-dose combination of two over-the-counter analgesics: acetaminophen (a non-selective cyclooxygenase inhibitor) and ibuprofen (a non-selective nonsteroidal anti-inflammatory drug) that work synergistically to reduce pain and fever.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Acetaminophen/Ibuprofen TARGET	Acetaminophen/Ibuprofen	Seoul National University Hospital	marketed	Analgesic/Antipyretic combination (NSAID + non-NSAID)	Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2), prostaglandin synthesis pathways
Acetaminophen and Ibuprofen	Acetaminophen and Ibuprofen	University of Manitoba	marketed	Analgesic/Antipyretic combination (NSAID + non-NSAID)	Prostaglandin synthesis pathway; COX-1/COX-2 enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Analgesic/Antipyretic combination (NSAID + non-NSAID) class)

Seoul National University Hospital · 1 drug in this class
University of Manitoba · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Acetaminophen/Ibuprofen — Competitive Intelligence Brief. https://druglandscape.com/ci/acetaminophen-ibuprofen. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing